Press Releases

Adult Malignant Glioma Therapeutics Market at a significant CAGR of 9.2% from 2018 to 2030

Share This Article

Adult Malignant Glioma Therapeutics Market – Snapshot

Gliomas account for more than 70% of all primary brain tumors. Glioblastoma is the most common (65%) and most malignant type of glioma. The global adult malignant glioma therapeutics market is characterized by an unmet medical need of improving survival rates. The market is witnessing rapid increase in novel pipeline drug candidates from major as well as emerging market players, supported by government policies to speed up the process of orphan drug approval. Hence, the global adult malignant glioma therapeutics market was valued at US$ 1.3 Bn in 2017 and is projected to expand at a significant CAGR of 9.2% from 2018 to 2026.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111989

Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline. The designation for orphan drug allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials along with seven years of market exclusivity upon regulatory approval. Moreover, expedited drug discovery process due to advent of high throughput technology and TCGA, and increase in discretionary funding for cancer research have led to the rise in clinical trials against malignant gliomas. However, significant attrition rate in clinical trials and staggeringly high prices of new-generation cancer drugs are the major factors likely to restrain the global adult malignant glioma therapeutics market during the forecast period.

In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme, which accounts for 12% to 15% of all intracranial tumors and 50% to 60% of all astrocytic tumors, is likely to be the most attractive segment during the forecast period, followed by anaplastic astrocytoma. Strong research and development focus of manufacturers, presence of significant patient population driving demand for effective therapeutics to improve the overall survival rate, and rapidly increasing pipeline of innovative novel drugs are attributed to the high growth of the segment. Based on therapy, the global market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy. The chemotherapy segment has been categorized into temozolomide, bevacizumab, carmustine, and others. The targeted drug therapy segment has been segmented into EGFR inhibitors, other monoclonal antibodies, and others. The market is characterized by a unique mix of patent expirations in the chemotherapy segment and rise in new patent approvals for targeted drug therapies. Loss of market exclusivity post patent expiration and reduction in branded drug prices due to competition from generic brands are likely to result in stagnant growth rate of the chemotherapy segment compared to targeted drug therapy. The targeted drug therapy segment is likely to dominate the global adult malignant glioma therapeutics market during the forecast period. This is because the segment comprises a promising pipeline covering diverse novel techniques such as gene therapy, nucleic acid therapies, lytic viruses, stem cells, nanoparticles, and others which are able to cross the blood brain barrier and target novel inhibition points rather than focusing on the inhibition of blood vessel formation.

View full report@ https://qyresearchmedical.com/report/adult-malignant-glioma-therapeutics-market-type-glioblastoma-multiforme-anaplastic-astrocytoma-anaplastic-oligodendroglioma-anaplastic-oligoastrocytoma-therapy-chemotherapy-targeted-drug-therapy-radiation-018-2030/111989

In terms of region, the global adult malignant glioma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017, accounting for over 37% share in terms of revenue. Europe was another major market for adult malignant glioma therapeutics in 2017. Technological advancement is a major driver of the market in North America and Europe. However, growth of the market in the near future is likely to depend on the combined prospects in technology and opportunity in the developing countries in Asia such as China, Japan, India, and South Korea. The market in Asia Pacific is anticipated to register an above average growth rate during the forecast period owing to relatively high patient population demanding affordable care and improvement in health care infrastructure in rapidly developing countries that aid the early diagnosis of malignant gliomas.

Major players operating in the global adult malignant glioma therapeutics market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111989/2900

The global adult malignant glioma therapeutics market has been segmented as follows:

Type

  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Anaplastic Oligoastrocytoma
  • Others

Therapy

  • Chemotherapy
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Others
  • Targeted Drug Therapy
  • EGFR Inhibitors
  • Other Monoclonal Antibodies
  • Others
  • Radiation Therapy

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Adult Malignant Glioma Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics by region
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis, by Region

5. Market Outlook
5.1. Adult Malignant Glioma Disease Overview
5.1.1 Glioblastoma Multiforme
5.1.2. Anaplastic Astrocytoma
5.1.3. Anaplastic Oligodendroglioma
5.1.4. Anaplastic Oligoastrocytoma
5.1.5. Others
5.2. Pipeline Analysis
5.2.1. Phase III & IV Drugs Market Forecast
5.2.1. Phase I & II Drug Candidates Comparative Analysis
5.3. Porter’s Five Force Analysis, by Region
5.4. Epidemiology of Glioma
5.4.1. Prevalence, by Country
5.4.2. Prevalence, by Type of Glioma
5.4.3. Incidence Rate, by Country
5.4.4. Incidence Rate, by Type of Glioma
5.5. Disease Burden by Key Regions / Country
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Rest of the World
5.6. SWOT Analysis, by Key Therapies
5.7. Regulatory Scenario, by Key Region / Country
5.8. Reimbursement Scenario, by Key Region / Country
5.9. Imaging Technologies Landscape in Glioma Analysis
5.10. Key Market Trends, by Region

6. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016– 2026
6.3.1. Glioblastoma Multiforme
6.3.2. Anaplastic Astrocytoma
6.3.3. Anaplastic Oligodendroglioma
6.3.4. Anaplastic Oligoastrocytoma
6.3.5. Others
6.4. Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Type

7. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Therapy
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
7.3.1. Chemotherapy
7.3.1.1. Temozolomide
7.3.1.2. Bevacizumab
7.3.1.3. Carmustine
7.3.1.4. Others
7.3.2. Targeted Drug Therapy
7.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
7.3.2.2. Other Monoclonal Antibodies
7.3.2.3. Others
7.3.3. Radiation Therapy
7.4. Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy

8. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

9. North America Adult Malignant Glioma Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
9.2.1. Glioblastoma Multiforme
9.2.2. Anaplastic Astrocytoma
9.2.3. Anaplastic Oligodendroglioma
9.2.4. Anaplastic Oligoastrocytoma
9.2.5. Others
9.3. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
9.3.1. Chemotherapy
9.3.1.1. Temozolomide
9.3.1.2. Bevacizumab
9.3.1.3. Carmustine
9.3.1.4. Others
9.3.2. Targeted Drug Therapy
9.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
9.3.2.2. Other Monoclonal Antibodies
9.3.2.3. Others
9.3.3. Radiation Therapy
9.4. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Country, 2016–2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By Therapy
9.5.3. By Country

10. Europe Adult Malignant Glioma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
10.2.1. Glioblastoma Multiforme
10.2.2. Anaplastic Astrocytoma
10.2.3. Anaplastic Oligodendroglioma
10.2.4. Anaplastic Oligoastrocytoma
10.2.5. Others
10.3. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
10.3.1. Chemotherapy
10.3.1.1. Temozolomide
10.3.1.2. Bevacizumab
10.3.1.3. Carmustine
10.3.1.4. Others
10.3.2. Targeted Drug Therapy
10.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
10.3.2.2. Other Monoclonal Antibodies
10.3.2.3. Others
10.3.3. Radiation Therapy
10.4. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By Therapy
10.5.3. By Country/Sub-region

11. Asia Pacific Adult Malignant Glioma Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
11.2.1. Glioblastoma Multiforme
11.2.2. Anaplastic Astrocytoma
11.2.3. Anaplastic Oligodendroglioma
11.2.4. Anaplastic Oligoastrocytoma
11.2.5. Others
11.3. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
11.3.1. Chemotherapy
11.3.1.1. Temozolomide
11.3.1.2. Bevacizumab
11.3.1.3. Carmustine
11.3.1.4. Others
11.3.2. Targeted Drug Therapy
11.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
11.3.2.2. Other Monoclonal Antibodies
11.3.2.3. Others
11.3.3. Radiation Therapy
11.4. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Rest of Asia Pacific
11.5. Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By Therapy
11.5.3. By Country/Sub-region

12. Latin America Adult Malignant Glioma Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Latin America Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
12.2.1. Glioblastoma Multiforme
12.2.2. Anaplastic Astrocytoma
12.2.3. Anaplastic Oligodendroglioma
12.2.4. Anaplastic Oligoastrocytoma
12.2.5. Others
12.3. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
12.3.1. Chemotherapy
12.3.1.1. Temozolomide
12.3.1.2. Bevacizumab
12.3.1.3. Carmustine
12.3.1.4. Others
12.3.2. Targeted Drug Therapy
12.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
12.3.2.2. Other Monoclonal Antibodies
12.3.2.3. Others
12.3.3. Radiation Therapy
12.4. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By Therapy
12.5.3. By Country/Sub-region

13. Middle East & Africa Adult Malignant Glioma Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2016–2026
13.2.1. Glioblastoma Multiforme
13.2.2. Anaplastic Astrocytoma
13.2.3. Anaplastic Oligodendroglioma
13.2.4. Anaplastic Oligoastrocytoma
13.2.5. Others
13.3. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2016–2026
13.3.1. Chemotherapy
13.3.1.1. Temozolomide
13.3.1.2. Bevacizumab
13.3.1.3. Carmustine
13.3.1.4. Others
13.3.2. Targeted Drug Therapy
13.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
13.3.2.2. Other Monoclonal Antibodies
13.3.2.3. Others
13.3.3. Radiation Therapy
13.4. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. MEA Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By Therapy
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1.Market Player – Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis, by Company (2017)
14.3.Market Footprint Analysis
14.4. Competitive Business Strategies
14.5. Company Profiles
14.5.1. Merck & Co., Inc.
14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.1.2. Product Portfolio
14.5.1.3. SWOT Analysis
14.5.1.4. Strategic Overview
14.5.1.5. Financial Overview
14.5.2. F. Hoffmann-La Roche Ltd.
14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.2.2. Product Portfolio
14.5.2.3. SWOT Analysis
14.5.2.4. Strategic Overview
14.5.2.5. Financial Overview
14.5.3. Arbor Pharmaceuticals
14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.3.2. Product Portfolio
14.5.3.3. SWOT Analysis
14.5.3.4. Strategic Overview
14.5.3.5. Financial Overview
14.5.4. Pfizer, Inc.
14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.4.2. Product Portfolio
14.5.4.3. SWOT Analysis
14.5.4.4. Strategic Overview
14.5.4.5. Financial Overview
14.5.5. AbbVie, Inc.
14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.5.2. Product Portfolio
14.5.5.3. SWOT Analysis
14.5.5.4. Strategic Overview
14.5.5.5. Financial Overview
14.5.6. Amgen, Inc.
14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.6.2. Product Portfolio
14.5.6.3. SWOT Analysis
14.5.6.4. Strategic Overview
14.5.6.5. Financial Overview
14.5.7. Bristol-Myers Squibb Company
14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.7.2. Product Portfolio
14.5.7.3. SWOT Analysis
14.5.7.4. Strategic Overview
14.5.7.5. Financial Overview
14.5.8. Sun Pharmaceuticals Ltd.
14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.8.2. Product Portfolio
14.5.8.3. SWOT Analysis
14.5.8.4. Strategic Overview
14.5.8.5. Financial Overview
14.5.9. Teva Pharmaceutical Industries Limited
14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.9.2. Product Portfolio
14.5.9.3. SWOT Analysis
14.5.9.4. Strategic Overview
14.5.9.5. Financial Overview
14.5.10. Emcure Pharmaceuticals Limited
14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.10.2. Product Portfolio
14.5.10.3. SWOT Analysis
14.5.10.4. Strategic Overview
14.5.10.5. Financial Overview

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111989/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Related Articles

Back to top button